Rigel Pharmaceuticals RIGL Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's total liabilities & equity?
- Rigel Pharmaceuticals (RIGL) reported total liabilities & equity of $504.61M in Q1 2026.
- How has Rigel Pharmaceuticals's total liabilities & equity changed year-over-year?
- Rigel Pharmaceuticals's total liabilities & equity increased by 186.8% year-over-year, from $175.97M to $504.61M.
- What is the long-term trend for Rigel Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's total liabilities & equity has grown at a 36.0% compound annual growth rate (CAGR), from $110.38M to $513.59M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.